Skip to content
Fotemustine

Structure via PubChem · Public domain (PubChem)

EntityQ1439555· pop 12· linked from 275 articles

Fotemustine

Sign in to save

Fotemustine is a nitrosourea alkylating agent used in the treatment of metastatic melanoma. It is available in Europe but has not been approved by the United States FDA. A study has shown that fotemustine produces improved response rates but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, re

Chemical data

Formula
C9H19ClN3O5P
Molecular weight
315.69 g/mol
IUPAC name
1-(2-chloroethyl)-3-(1-diethoxyphosphorylethyl)-1-nitrosourea
SMILES
CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC
InChIKey
YAKWPXVTIGTRJH-UHFFFAOYSA-N
XLogP
0.9
Polar surface area
97.3 Ų
H-bond donors
1
H-bond acceptors
6
Formal charge
0

via PubChem

Drug data · ChEMBL

Max clinical phase
Phase 3
Molecule type
Small molecule
Indications
neoplasm, glioblastoma multiforme, cutaneous melanoma, melanoma

via ChEMBL · EBI

Research

415 papers

via PubMed

Wikidata facts

Mass
315.075
Has use
medication
Show 4 more facts
chemical formula
C₉H₁₉ClN₃O₅P
canonical SMILES
CCOP(=O)(C(C)NC(=O)N(CCCl)N=O)OCC
subject has role
antineoplastic
Commons category
Fotemustine
Sources (2)

via Wikidata · CC0